On Aug. 24, 2021, Adamis Pharma announced publication in the peer reviewed journal, Clinical Immunology, entitled ﾓTempol, a novel antioxidant, inhibits both activated T cell and APC. The studies conducted at the Human Immune Monitoring Center at Stanford University investigated the effects of Tempol, an investigational drug, on immune cells from COVID-19 patients.

The authors concluded ﾓPreincubation of immune cells with Tempol resulted in a significant decrease in multiple T cell and APC-derived cytokines from both cells of COVID-19 and uninfected donors.